Associated equity: Amoeba
Amoéba is a greentech based in France, which aims to become a major player in treating microbiological risk in the crop protection and cosmetic sectors. Based on the natural properties of a unique, exclusively patented microorganism, its biological solutions offer a viable alternative to the chemical products widely used in the industry today.
Amoeba — 1 video in collection
Amoeba is developing biological fungicides for treating diseases such as mildews and rusts, which have a major economic impact on the production globally of a wide range of crops including vines, potatoes, vegetables, cereals and bananas. These novel fungicides are based on the characteristics of the Willaertia magna C2c Maky amoeba.
In this interview, Amoeba CEO and chairman Fabrice Plasson explains why there is so much interest in biological alternatives to conventional crop protection products at present and describes both the progress the company has made so far in commercialising its biofungicides and the additional steps required before Amoeba starts to generate revenues from this technology.